Salvus Wealth Management LLC Has $333,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Salvus Wealth Management LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 40.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,967 shares of the company’s stock after buying an additional 563 shares during the quarter. Salvus Wealth Management LLC’s holdings in Zoetis were worth $333,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Nova R Wealth Inc. acquired a new stake in shares of Zoetis during the 1st quarter valued at about $232,000. Navalign LLC lifted its position in shares of Zoetis by 3.3% during the 1st quarter. Navalign LLC now owns 5,049 shares of the company’s stock worth $854,000 after buying an additional 161 shares during the period. Harbor Investment Advisory LLC boosted its stake in shares of Zoetis by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 6,599 shares of the company’s stock valued at $1,117,000 after purchasing an additional 764 shares in the last quarter. Global Assets Advisory LLC acquired a new position in Zoetis in the first quarter valued at about $8,831,000. Finally, Anderson Hoagland & Co. boosted its holdings in shares of Zoetis by 5.6% in the 1st quarter. Anderson Hoagland & Co. now owns 21,633 shares of the company’s stock worth $3,531,000 after acquiring an additional 1,156 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Zoetis Price Performance

ZTS stock traded down $0.83 during mid-day trading on Tuesday, hitting $171.01. The stock had a trading volume of 80,895 shares, compared to its average volume of 2,939,374. The firm has a fifty day simple moving average of $167.00 and a 200 day simple moving average of $179.11. The firm has a market capitalization of $78.03 billion, a P/E ratio of 32.84, a P/E/G ratio of 2.66 and a beta of 0.89. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.31 earnings per share. As a group, research analysts forecast that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is presently 33.33%.

Analysts Set New Price Targets

Several analysts have recently commented on ZTS shares. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Stifel Nicolaus dropped their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Piper Sandler restated an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group dropped their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Finally, HSBC cut their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.